Spain Approves Oryzon-Sponsored VIVALDI AML Study
Spain authorized CETLAM-sponsored Phase Ib pilot VIVALDI, evaluating iadademstat with azacitidine and venetoclax in newly diagnosed AML subgroups associated with suboptimal responses to standard care. Oryzon plans to start the potentially registrational ALICE-3 Phase III study in 2027.